Drug Overview
Xadago (safinamide; Newron Pharmaceuticals/US WorldMeds/Zambon/Meiji Seika Pharma) has a novel dual mechanism of action, based on the enhancement of the dopaminergic function through the reversible inhibition of monoamine oxidase B (MAO-B) and inhibition of excessive glutamate release by blocking the activity of the voltage-dependent sodium channels. Although Xadago was originally developed by Newron across the spectrum of Parkinson’s disease, it is approved only for mid-late stage Parkinson’s disease patients receiving levodopa and experiencing motor fluctuations. Its first approval came in the EU in February 2015, with a subsequent expansion to the US in March 2017.
Newron has sought out several commercial partners for Xadago, including out-licensing global rights to Zambon and Asian territory rights to Meiji Seika. Zambon has subsequently partnered with US WorldMeds for the drug’s commercialization in the US, while Eisai has obtained exclusive rights to Xadago in Japan.
Xadago (safinamide; Newron Pharmaceuticals/US WorldMeds/Zambon/Meiji Seika Pharma) has a novel dual mechanism of action, based on the enhancement of the dopaminergic function through the reversible inhibition of monoamine oxidase B (MAO-B) and inhibition of excessive glutamate release by blocking the activity of the voltage-dependent sodium channels. Although Xadago was originally developed by Newron across the spectrum of Parkinson’s disease, it is approved only for mid-late stage Parkinson’s disease patients receiving levodopa and experiencing motor fluctuations. Its first approval came in the EU in February 2015, with a subsequent expansion to the US in March 2017.
Newron has sought out several commercial partners for Xadago, including out-licensing global rights to Zambon and Asian territory rights to Meiji Seika. Zambon has subsequently partnered with US WorldMeds for the drug’s commercialization in the US, while Eisai has obtained exclusive rights to Xadago in Japan.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
